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Abstract
• Prostate cancer and metabolic syndrome are both
prevalent among men in developed countries with peak
incidence after age 50.
• Prostate cancer has no known modifiable risk factors.
• Most risk factors for metabolic syndrome are modifiable.
• If metabolic syndrome is identified as contributing to the
risk of prostate cancer it would give an element of self
determination to men at risk for prostate cancer.
• Past studies provide conflicting results in the correlation
between these two conditions.
• A literature review was performed to evaluate
consistencies in current literature.
• Metabolic syndrome or its components do not increase the
risk of developing overall prostate cancer.
• Metabolic syndrome does increase mortality from prostate
cancer.
• Men with metabolic syndrome are found to have higher
grades of disease upon diagnosis of prostate cancer

Research Question

Applicability to Clinical
Practice

Results

• Are men with a diagnosis of metabolic syndrome at
increased risk for developing prostate cancer compared to
men without.?

• Practitioners should not alter their practice from established
guidelines to screen for prostate cancer in the presence of
metabolic conditions.

• Prostate cancer is defined as overall cases.
• No differentiation is made between high and low grade
cancer based of Gleason score or presence of
symptoms.
• Do any of the individual components of metabolic syndrome
increase the risk for developing prostate cancer?
• Metabolic syndrome components include
• Above normal serum triglyceride levels
• Above normal serum glucose levels
• Below normal serum HDL
• Elevated blood pressure
• Above normal weight

• Current prostate cancer screening guidelines.
• American College of Physicians
• Shared decision making age 50-60 with >15 years
of life expectancy.
• American Cancer Society
(Haggstrom, 2012)

• This figure is a graphical representation of the
relationship between metabolic syndrome components
and both overall prostate cancer and death from prostate
cancer.
• Model 1 Corrected for random error using the regression
dilution ratio.
• Model 2 corrected for random error using regression
calibration.

• Shared Decision Making at age 50 for men of
average risk.
• Providers should be mindful that men with metabolic
disorders will likely have more advanced prostate cancer
when diagnosed than men without.
• Be mindful of the of the importance of preventative medicine
when caring for patients with complex medical histories.
• Prostate cancer screening requires shared decision making.
Knowledge of advanced disease should be part of the
conversation about screening.

• Composite score is as compilation of the z scores
calculated for each individual component.

Introduction
• Risk factors for prostate cancer include only: age, race
and family history.
• In the US 180,000 new cases of prostate cancer and
26,000 deaths per year.
• Low sensitivity of screening tests leads to unnecessary
procedures and complications.
• Clinically insignificant cancer is often diagnosed on
autopsy.
• Risk factors for metabolic syndrome include high fat low
fiber diet and sedentary lifestyle among others.
• Metabolic syndrome is defined as having 3 oft of 5
abnormal: Triglycerides, serum glucose, HDL, blood
pressure and weight.

Statement of the Problem
• Both conditions are found in similar cohorts.
• Metabolic syndrome has been proven modifiable through
lifestyle modification while Prostate Cancer is unavoidable.
• Past literature makes differing conclusions on the
correlation between the two.

Literature Review

Discussion

• Metabolic syndrome does not increase the risk of
developing cancer. Diabetes may be protective against
developing prostate cancer (Wallner, 2010).

• Due to inconsistencies in the definition of metabolic
syndrome, cross study comparisons must be qualitative
which leads to inaccuracies.

• There is no significant correlation found between metabolic
syndrome and prostate cancer (Lawrence,2012).
• No individual components of metabolic syndrome or any
composite grouping of them increase the risk of prostate
cancer, increased mortality found (Haggstrom, 2012).

• For example one study will classify hypertension by
blood pressure measurement while others use a
prescription of antihypertensive medication to
define it.
• The strongest evidence available indicates no positive
correlation between metabolic syndrome as a whole and
overall prostate cancer.

• Metabolic syndrome specifically including hypertension
increased the risk of prostate cancer. Hypertension alone
does not increase risk, metabolic syndrome without
hypertension does not increase risk (Radisauskas, 2016).
• Hypertension does increase the risk of overall prostate
cancer (Liang, 2016).
• Men with metabolic syndrome have greater risk of high
grade prostate cancer than those without (Zhang, 2015)
• No individual component of metabolic syndrome increases
the risk of prostate cancer (Bhindi, 2014).
• Men with metabolic syndrome have higher grades of
disease upon prostate biopsy (De Nunzio, 2011).
• One metabolic syndrome component was protective
against prostate cancer, 2 or more components were
associated with higher grades of cancer on diagnosis
(Sourbeer, 2014).

• Studies indicating individual components of metabolic
syndrome increase the risk of prostate cancer have
weaknesses which undermine their results, coupled with
weak statistical correlations.
• Good quality evidence supports a correlation between the
number of metabolic components a man has and the
grade of prostate cancer he has upon diagnosis.
• This is further supported by strong evidence for
increased mortality from prostate cancer among
men with metabolic syndrome or components.
• Further analysis is needed to investigate the degree to
which diabetes is protective against prostate cancer.
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